BioCentury
ARTICLE | Clinical News

Diamyd: Phase III data

May 16, 2011 7:00 AM UTC

Top-line data from a double-blind, European Phase III trial in >320 patients ages 10-20 with newly diagnosed Type I diabetes showed that 2 or 4 injections of 20 µg subcutaneous Diamyd missed the prima...